Loss of Interleukin Receptor-Associated Kinase 4 Signaling Suppresses Amyloid Pathology and Alters Microglial Phenotype in a Mouse Model of Alzheimer's Disease

Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio 44106
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.34). 10/2012; 32(43):15112-23. DOI: 10.1523/JNEUROSCI.1729-12.2012
Source: PubMed


Alzheimer's disease (AD) is typified by the deposition of amyloid in the brain, which elicits a robust microglial-mediated inflammatory response that is associated with disease exacerbation and accelerated progression. Microglia are the principal immune effector cells in the brain and interact with fibrillar forms of Aβ (fAβ) through a receptor complex that includes Toll-like receptors (TLR) 2/4/6 and their coreceptors. Interleukin receptor-associated kinases (IRAKs) are essential intracellular signaling molecules for transduction of TLR signals. Studies of mouse models of AD in which the individual TLRs are knocked out have produced conflicting results on roles of TLR signaling in amyloid homeostasis. Therefore, we disrupted a common downstream TLR signaling element, IRAK4. We report that microglial IRAK4 is necessary in vitro for fAβ to activate the canonical pro-inflammatory signaling pathways leading to activation of p38, JNK, and ERK MAP kinases and to generate reactive oxygen species. In vivo the loss of IRAK4 function results in decreased Aβ levels in a murine model of AD. This was associated with diminished microgliosis and astrogliosis in aged mice. Analysis of microglia isolated from the adult mouse brain revealed an altered pattern of gene expression associated with changes in microglial phenotype that were associated with expression of IRF transcription factors that govern microglial phenotype. Further, loss of IRAK4 function also promoted amyloid clearance mechanisms, including elevated expression of insulin-degrading enzyme. Finally, blocking IRAK function restored olfactory behavior. These data demonstrate that IRAK4 activation acts normally to regulate microglial activation status and influence amyloid homeostasis in the brain.

Download full-text


Available from: Brent Cameron, Jun 23, 2014
  • Source
    • "on the " inflammatory " states of glia . Indeed , the data from our time course provided in this study show the importance of using multiple approaches ( behavior , glial specific mRNA , morphol - ogy ) when reporting on the level of microglial activation . We acknowledge that when microglia are chronically activated in neurodegenerative disease ( Cameron et al . , 2012 ; Cunning - ham et al . , 2005a ) , CNS infection ( Nayak et al . , 2013 ) , trau - matic CNS injury ( Cao et al . , 2012 ; Detloff et al . , 2008 ; Kumar et al . , 2013 ) , or stress ( Kreisel et al . , 2014 ; Wohleb et al . , 2011 ) a de - ramified Iba - 1 profile of microglia is likely a good representation of a proinflammatory profi"
    [Show abstract] [Hide abstract]
    ABSTRACT: Activation of the peripheral immune system elicits a coordinated response from the central nervous system. Key to this immune to brain communication is that glia, microglia, and astrocytes, interpret and propagate inflammatory signals in the brain that influence physiological and behavioral responses. One issue in glial biology is that morphological analysis alone is used to report on glial activation state. Therefore, our objective was to compare behavioral responses after in vivo immune (lipopolysaccharide, LPS) challenge to glial specific mRNA and morphological profiles. Here, LPS challenge induced an immediate but transient sickness response with decreased locomotion and social interaction. Corresponding with active sickness behavior (2-12 h), inflammatory cytokine mRNA expression was elevated in enriched microglia and astrocytes. Although proinflammatory cytokine expression in microglia peaked 2-4 h after LPS, astrocyte cytokine, and chemokine induction was delayed and peaked at 12 h. Morphological alterations in microglia (Iba-1(+) ) and astrocytes (GFAP(+) ), however, were undetected during this 2-12 h timeframe. Increased Iba-1 immunoreactivity and de-ramified microglia were evident 24 and 48 h after LPS but corresponded to the resolution phase of activation. Morphological alterations in astrocytes were undetected after LPS. Additionally, glial cytokine expression did not correlate with morphology after four repeated LPS injections. In fact, repeated LPS challenge was associated with immune and behavioral tolerance and a less inflammatory microglial profile compared with acute LPS challenge. Overall, induction of glial cytokine expression was sequential, aligned with active sickness behavior, and preceded increased Iba-1 or GFAP immunoreactivity after LPS challenge. GLIA 2015.
    Glia 10/2015; DOI:10.1002/glia.22930 · 6.03 Impact Factor
  • Source
    • "Quantification of pro-or anti-inflammatory gene expression was performed as previously described (Cameron et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is characterized by impaired clearance of amyloid beta (Aβ) peptides, leading to the accumulation of Aβ in the brain and subsequent neurodegeneration and cognitive impairment. ApoE plays a critical role in the proteolytic degradation of soluble forms of Aβ. This effect is dependent upon lipidation of ApoE by ABCA1-mediated transfer of phospholipids and cholesterol. ApoE and ABCA1 are induced by the action of the RXR agonist, bexarotene. We have previously shown that bexarotene reduces Aβ levels in AD mouse models and we have hypothesized that this effect requires ABCA1-mediated lipidation of ApoE. To test this hypothesis, we crossed ABCA1-deficient (ABCA1 KO) mice with the APP/PS1 model of AD. Aged ABCA1 WT and ABCA1 KO APP/PS1 mice were treated for 7 days with vehicle or bexarotene (100 mg/kg/day). Bexarotene reduced levels of soluble Aβ 1-40 and 1-42 in the hippocampus of ABCA1 WT but not ABCA1 KO APP/PS1 mice. In contrast, insoluble levels of Aβ, and plaque loads were unaffected by bexarotene in this study. ABCA1 KO mice had increased levels of inflammation compared with ABCA1 WT mice. Bexarotene also increased most inflammatory gene markers evaluated. The effect of bexarotene on microglial inflammatory profiles, however, was independent of ABCA1 genotype. Importantly, bexarotene ameliorated deficits in novel object recognition in ABCA1 WT but not ABCA1 KO APP/PS1 mice. These data indicate that ABCA1-induced lipidation of ApoE is necessary for the ability of bexarotene to clear hippocampal soluble Aβ and ameliorate cognitive deficits.
    Journal of Neuroimmune Pharmacology 07/2015; DOI:10.1007/s11481-015-9627-8 · 4.11 Impact Factor
    • "Acompletepictureofthecontributionsofeachgroupof cytokinesandchemokinestoAβOtoxicityisstillnotavailable. Forexample,knockoutofinterleukin-10(IL-10),ananti- inflammatorycytokine,amelioratedcognitiveimpairmentin APP/PS1mice,consistentwithenhancedIL-10signalingin ADbrains(Guillot-Sestieretal.,2015).AdministrationofIL- 10inAPP/PS1micereducedAβphagocytosis,contraryto observationsinIL-10-depletedanimals(Guillot-Sestieretal., 2015).Suppressionofinterleukinreceptor-associatedkinase4 (IRAK4),adownstreameffectorofTLRactivity,resultedin improvedclearanceandreducedAβlevelsinAPP/PS1mice (Cameronetal.,2012).Similarly,overexpressionofinterleukin- 1β,apro-inflammatorycytokine,reducedamyloidplaque burdenin3×Tgmice,althoughtaupathologywasworsened (Ghoshetal.,2013). Uponactivation,microgliaactaspotentphagocyticcells, andthismaybeimportantasadefensemechanismtoprevent earlyAβdeposition.However,significantaccumulationofAβOs appearstoimpairphagocyticactivityofmicroglia.Stimulation ofthePPARy/RXRaheterodimerbyselectiveagonistsintensifies Aβphagocytosisbymicroglialcellsandimprovesmemory performanceinAPP/PS1mice(Yamanakaetal.,2012).This appearstobemediatedbyCD36,amoleculethathasreduced Ferreiraetal. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and affects millions of people worldwide. As the number of AD cases continues to increase in both developed and developing countries, finding therapies that effectively halt or reverse disease progression constitutes a major research and public health challenge. Since the identification of the amyloid-b peptide (Ab) as the major component of the amyloid plaques that are characteristically found in AD brains, a major effort has aimed to determine whether and how Ab leads to memory loss and cognitive impairment. A large body of evidence accumulated in the past 15 years supports a pivotal role of soluble Ab oligomers (AbOs) in synapse failure and neuronal dysfunction in AD. Nonetheless, a number of basic questions, including the exact molecular composition of the synaptotoxic oligomers, the identity of the receptor(s) to which they bind, and the signaling pathways that ultimately lead to synapse failure, remain to be definitively answered. Here, we discuss recent advances that have illuminated our understanding of the chemical nature of the toxic species and the deleterious impact they have on synapses, and have culminated in the proposal of an Ab oligomer hypothesis for Alzheimer’s pathogenesis. We also highlight outstanding questions and challenges in AD research that should be addressed to allow translation of research findings into effective AD therapies.
    Frontiers in Cellular Neuroscience 05/2015; 9. DOI:10.3389/fncel.2015.00191 · 4.29 Impact Factor
Show more